<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Jan. 14, 2019 (HealthDay News) — Topical application of a transient receptor potential vanilloid subfamily, member 1 (TRPV1) antagonist may be an effective and safe treatment for patients with mild-to-moderate atopic dermatitis (AD), according to a phase IIb study published online Jan. 8 in the British Journal of Dermatology<\/i>.<\/p>\n
Y.W. Lee, from Konkuk University School of Medicine in Seoul, South Korea, and colleagues assessed the clinical efficacy and safety of PAC-14028, a TRPV1 antagonist, via topical application in 194 patients with mild-to-moderate AD. Participants were randomly assigned to receive either PAC-14028 cream 0.1 percent, 0.3 percent, or 1 percent or vehicle cream twice daily for eight weeks.<\/p>\n
The researchers found that Investigator’s Global Assessment (IGA) success rates at week 8 were 14.58 percent for vehicle cream, 42.55 percent for 0.1 percent PAC-14028 cream, 38.3 percent for 0.3 percent PAC-14028 cream, and 57.45 percent for 1 percent PAC-14028 cream. Statistically significant differences were noted between the vehicle and treatment groups in the IGA success rates with two-grade improvement in particular. In addition, there was a trend toward improvement in the Scoring of Atopic Dermatitis index, Eczema Area and Severity Index 75\/90, sleep disturbance score, and pruritus visual analogue scale. The researchers reported no significant safety issues.<\/p>\n
“PAC-14028 cream is a promising new treatment option for patients with mild-to-moderate AD based on the favorable tolerability profile and the improved efficacy in treating AD observed in the present study,” the authors write.<\/p>\n
Several authors disclosed financial ties to pharmaceutical and personal care companies, including AmorePacific Corp., which manufactures PAC-14028 and funded the study.<\/p>\n